SEC 13F Intelligence

Managers / Q1 2020 · view latest →

Logos Global Management LP

CIK 0001792126 · 1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO, CA, 94129 · 4158014660

Reported Value
$263M
Q1 2020
Positions
41
Filings on Record
29
2019–present window
Filed
May 15, 2020
original filing

Summary

Logos Global Management LP reported $263M in U.S.-listed holdings across 41 positions for Q1 2020.

Its largest position, ABBV, represents 7.7% of the portfolio.

Compared with Q4 2019, the fund opened 21 new positions and exited 19.

Portfolio Metrics

Turnover
+44.7%
vs prior filed quarter
Top-10 Concentration
+50.5%
share of reported value
Largest Position
+7.7%
Abbvie
New / Exited
21 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $406MQ4 ’19Q1 ’20: $263MQ2 ’20: $500MQ3 ’20: $781MQ4 ’20: $1.2BQ4 ’20Q1 ’21: $1.0BQ2 ’21: $1.2BQ3 ’21: $1.4BQ4 ’21: $970MQ4 ’21Q1 ’22: $771MQ2 ’22: $545MQ3 ’22: $813MQ4 ’22: $854MQ4 ’22Q1 ’23: $699MQ2 ’23: $735MQ3 ’23: $750MQ4 ’23: $1.1BQ4 ’23Q1 ’24: $1.2BQ2 ’24: $2.5BQ3 ’24: $927MQ4 ’24: $855MQ4 ’24Q1 ’25: $563MQ2 ’25: $904MQ3 ’25: $1.1BQ4 ’25: $1.7BQ4 ’25Q1 ’26: $2.0Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 80.2%Other: 18.0%Right: 1.8%
  • Common Stock · 80.2% · $211M
  • Other · 18.0% · $47M
  • Right · 1.8% · $5M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ABBVABBVIE INCNEW+265.6K265.6K+$20M$20M
MRNAMODERNA INCNEW+460.0K460.0K+$14M$14M
BMYBRISTOL-MYERS SQUIBB CONEW+194.5K194.5K+$11M$11M
GBTUSDGLOBAL BLOOD THERAPEUTICS INNEW+185.9K185.9K+$9M$9M
PASSAGE BIO INCNEW+603.3K603.3K+$9M$9M
VRTXVERTEX PHARMACEUTICALS INCNEW+33.2K33.2K+$8M$8M
VERASTEM INCNEW+2.33M2.33M+$6M$6M
TXG10X GENOMICS INCNEW+72.8K72.8K+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

39 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ABBVABBVIE INChistory →COM7.70%$20M265.6K
2SRPTSAREPTA THERAPEUTICS INChistory →COM6.97%$18M187.3K
3BMYBRISTOL-MYERS SQUIBB COCOM · RIGHT 99/99/99995.97%$16M1.47M
4MYOKEURMYOKARDIA INChistory →COM5.35%$14M300.0K
5MRNAMODERNA INChistory →COM5.24%$14M460.0K
6ASCENDIS PHARMA A SSPONSORED ADR5.14%$14M120.0K
7RETAEURREATA PHARMACEUTICALS INChistory →CL A4.52%$12M82.3K
8ZYMEUSDZYMEWORKS INChistory →COM4.11%$11M304.4K
91K0IGM BIOSCIENCES INChistory →COM3.71%$10M173.9K
10GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory →COM3.61%$9M185.9K
11PASSAGE BIO INCCOM3.41%$9M603.3K
12VRTXVERTEX PHARMACEUTICALS INChistory →COM3.01%$8M33.2K
13BLUBELLUS HEALTH INC NEWhistory →COM NEW2.94%$8M775.4K
14IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM2.82%$7M247.2K
15FULCFULCRUM THERAPEUTICS INChistory →COM2.42%$6M532.5K
16ETNBGBP89BIO INChistory →COM2.37%$6M247.0K
17MOLECULAR TEMPLATES INCCOM2.22%$6M438.8K
18VERASTEM INCCOM2.10%$6M2.33M
19KARUNA THERAPEUTICS INCCOM1.91%$5M69.7K
20TXG10X GENOMICS INChistory →CL A COM1.73%$5M72.8K
21CRISPR THERAPEUTICS AGNAMEN AKT1.70%$4M105.5K
222655787DBLUEPRINT MEDICINES CORPhistory →COM1.67%$4M75.0K
23ALNYALNYLAM PHARMACEUTICALS INChistory →COM1.64%$4M39.6K
24FATEFATE THERAPEUTICS INChistory →COM1.63%$4M193.1K
25AM6AMICUS THERAPEUTICS INChistory →COM1.57%$4M446.9K
26TREURTRILLIUM THERAPEUTICS INChistory →COM NEW1.53%$4M995.6K
27LIFESCI ACQUISITION CORPUNIT 03/31/20251.52%$4M400.0K
28ZGNXEURZOGENIX INChistory →COM NEW1.43%$4M152.1K
29IMMUIMMUNOMEDICS INChistory →COM1.42%$4M276.6K
30MRTXEURMIRATI THERAPEUTICS INChistory →COM1.36%$4M46.4K
31BDTXBLACK DIAMOND THERAPEUTICS Ihistory →COM1.05%$3M123.5K
32SELECTA BIOSCIENCES INCCOM1.02%$3M1.11M
33TGTXTG THERAPEUTICS INCCOM0.93%$2M249.8K
34CYTKCYTOKINETICS INCCOM NEW0.87%$2M193.1K
35SG7SAGE THERAPEUTICS INCCOM0.76%$2M69.6K
36NERVGBPMINERVA NEUROSCIENCES INCCOM0.71%$2M309.7K
37YB4PSAVARA INCCOM0.45%$1M614.0K
38RVMDREVOLUTION MEDICINES INCCOM0.44%$1M53.0K
39RCKTROCKET PHARMACEUTICALS INCCOM0.08%$221,00015.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$2.0B66May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.7B69Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.1B59Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$904M51Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$563M39May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$855M47Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$927M55Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024REVEALED$2.5B111Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.2B57May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.1B53Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$750M56Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$735M51Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$699M43May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$854M40Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$813M39Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$545M32Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$771M47May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$970M66Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.4B57Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B58Aug 17, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$1.0B53May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.2B59Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$781M46Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$500M46Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$263M41May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$406M40Feb 14, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.